Your browser doesn't support javascript.
Frequency and temporal evolution of COVID-19 vaccination rate among oncological patients undergoing 18F-FDG-PET.
Skawran, Stephan; Schiesser, Helen; Maurer, Alexander; Sartoretti, Thomas; Dittli, Manuel; Mader, Cäcilia; Curioni-Fontecedro, Alessandra; Berger, Christoph; Huellner, Martin W; Messerli, Michael.
  • Skawran S; Department of Nuclear Medicine, University Hospital Zurich, Switzerland; University of Zurich, Switzerland. Electronic address: stephan.skawran@usz.ch.
  • Schiesser H; Department of Nuclear Medicine, University Hospital Zurich, Switzerland; University of Zurich, Switzerland.
  • Maurer A; Department of Nuclear Medicine, University Hospital Zurich, Switzerland; University of Zurich, Switzerland.
  • Sartoretti T; Department of Nuclear Medicine, University Hospital Zurich, Switzerland; University of Zurich, Switzerland.
  • Dittli M; Department of Nuclear Medicine, University Hospital Zurich, Switzerland; University of Zurich, Switzerland.
  • Mader C; Department of Nuclear Medicine, University Hospital Zurich, Switzerland; University of Zurich, Switzerland.
  • Curioni-Fontecedro A; University of Zurich, Switzerland; Department of Medical Oncology, University Hospital Zurich, Switzerland.
  • Berger C; University of Zurich, Switzerland; Division of Infectious Diseases and Children's Research Centre, University Children's Hospital Zurich, Switzerland.
  • Huellner MW; Department of Nuclear Medicine, University Hospital Zurich, Switzerland; University of Zurich, Switzerland.
  • Messerli M; Department of Nuclear Medicine, University Hospital Zurich, Switzerland; University of Zurich, Switzerland.
Vaccine ; 40(52): 7640-7645, 2022 Dec 12.
Article in English | MEDLINE | ID: covidwho-2096121
ABSTRACT

PURPOSE:

To evaluate the temporal evolution of vaccination against COVID-19 in a Swiss oncological cohort.

METHODS:

History of complete vaccination (i.e. at least two vaccine doses) against COVID-19 of patients undergoing oncological 18F-FDG PET/CT between February and September 2021 (n = 2613) was taken. Vaccination rate was compared with age-matched national data from the Swiss Federal Office of Public Health. Subgroup differences in temporal evolution of vaccination rate were analyzed by fitting a generalized linear model and determined by significant interaction between, sex, oncological diagnosis, and month of examination.

RESULTS:

Rate of complete vaccination against COVID-19 steadily increased and reached 81 % in September 2021. The fraction of vaccinated patients in the oncological cohort was higher in the beginning and approached the fraction in the age-matched general Swiss population at the end of the study period. Month of exam (p < 0.001) was the only significant predictor of the vaccination rate.

CONCLUSION:

Vaccination rate against COVID-19 in a Swiss oncological cohort increased steadily from February to September 2021. Compared to the age-matched general population it was higher in the beginning and similar by the end of the study period. Ethics approval Trial registration BASEC 2021-00444, Ethikkommission Zürich (Cantonal Ethics Committee Zurich), Switzerland, registered February 24th 2021.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Fluorodeoxyglucose F18 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Vaccine Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Fluorodeoxyglucose F18 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Vaccine Year: 2022 Document Type: Article